Small Interfering RNA (SiRNA) Market Size (2024 – 2030)

The Global Small Interfering RNA (SiRNA) Market was valued at USD 13 billion and is projected to reach a market size of USD 40.2 billion by the end of 2030. The market is anticipated to expand at a compound annual growth rate (CAGR) of 17.5% between 2024 and 2030.

The cutting edge of genetic therapy is small interfering RNA (siRNA), sometimes known as silencing RNA because of its potent ability to mute overexpressed genes linked to a wide range of illnesses. SiRNAs are extensively employed in analyzing cellular phenotypes and the dissection of gene activities. They are essential in the discovery of new pathways and the confirmation of therapeutic targets in the treatment of serious illnesses like AIDS, hepatitis, and cancer. By utilizing the enzymatic machinery of the cell, siRNAs enable the targeted degradation of target gene mRNA, thereby reducing the overexpression of the harmful gene. SiRNA therapeutics show improved efficacy compared to conventional medications, providing exciting new opportunities for therapeutic intervention. This therapeutic strategy uses novel delivery technologies for effective and targeted gene silencing. It includes liposome- and nanoparticle-based systemic therapy. With its unmatched capacity to alter gene expression, siRNA becomes a game-changing instrument in the fight for precision medicine, providing hope for the cure of a wide range of crippling illnesses.

Key Market Insights:

North America commands a substantial 45% share of the global siRNA market, with the oncology segment reigning supreme at 55%. Asia Pacific emerges as a promising market player, capturing 25%. Liposome-based therapy secures a significant 35% share of targeted drug delivery. The U.S. Food and Drug Administration (FDA) has approved only one liposomal formulation—nano liposomal irinotecan, or Nivida—for the treatment of metastatic pancreatic cancer as of 2022. Research institutions contribute to 20% of siRNA market development, and the regulatory landscape impacts 30% of market growth. Researchers Shou-wei Ding and Shabihah Shahrudin at the University of California, Riverside have discovered a new isoform of the Dicer enzyme and have shown it to be protective against RNA viruses in stem cell therapies for both humans and mice. Emerging technologies drive 40% of siRNA market innovation, and healthcare spending influences 50% of market expansion. With such robust statistics, the siRNA market demonstrates significant potential for growth and innovation.

Global Small Interfering RNA (SiRNA) Market Drivers:

SiRNA's greater efficiency as compared to other reverse genetic technologies is thought to be the main driver of the market's expansion.

siRNA is widely employed to evaluate several cellular characteristics, such as cell differentiation, death, cytokinesis, and insulin signaling. Due to siRNA's great potential for gene silencing, numerous target-specific therapeutic applications have been developed to validate targets in conditions like hepatitis, HIV infection, cancer, and others. A strong healthcare infrastructure, a growing number of clinical trials, quick pre-clinical development, increased government financing for research and development, and these factors all contribute to the market's growth. Additionally, small interfering RNAs (siRNAs) emerge as noteworthy developments since cancer continues to be the world's top cause of mortality. Through a mechanism called RNA interference (RNAi), they have a significant impact on controlling gene expression, which positively contributes to market expansion.

Unlocking Precision Medicine is the Surge in Demand for siRNA-Based Therapies.

The escalating demand for targeted therapeutics has catalyzed a paradigm shift in the landscape of medical treatment. Traditional medications, with their broad-reaching effects, often lack precision, impacting both healthy and diseased cells. In contrast, small interfering RNA (siRNA) technology presents a revolutionary approach by directly targeting the root cause of diseases through the silencing of specific genes. This precision-oriented strategy holds immense promise for addressing a diverse array of illnesses, encompassing genetic disorders, cancers, and viral infections. The burgeoning prevalence of these conditions, coupled with the rising awareness of personalized medicine, is driving the exponential growth in demand for siRNA-based therapies. With their ability to tailor treatments to individual genetic profiles and disease pathways, siRNA-based therapies represent a transformative leap forward in the quest for precision medicine, offering renewed hope for patients and clinicians alike in the battle against complex diseases.

Global Small Interfering RNA (SiRNA) Market Restraints and Challenges:

In the promising realm of siRNA therapeutics, several hurdles pose challenges to widespread adoption. High manufacturing costs and the complexity of delivery methods contribute to the expense of siRNA treatments, potentially limiting access for patients. Regulatory barriers, particularly those concerning safety and efficacy testing, prolong the market entry process for new siRNA drugs, further impeding their availability. Moreover, the risk of off-target effects, where siRNA inadvertently silences unintended genes, necessitates meticulous design and extensive clinical trials to ensure safety and efficacy. These obstacles can hamper market growth and hinder the realization of siRNA's full potential in medical practice. To overcome these challenges, ongoing research efforts are imperative to enhance production efficiency, develop safer delivery systems, and minimize off-target effects. By addressing these concerns, the path can be cleared for broader adoption of siRNA therapies, ultimately expanding treatment options and improving outcomes for patients grappling with a diverse range of diseases.

Global Small Interfering RNA (SiRNA) Market Opportunities:

The future of the global siRNA market shimmers with exciting opportunities. With the successful commercialization of several siRNA therapies for rare diseases, the potential for siRNA to tackle a broader range of conditions is vast. Oncology represents a significant opportunity, with siRNA targeting specific cancer-causing genes. siRNA's ability to silence previously "undruggable" targets holds immense promise. Furthermore, siRNA's potential application in areas like neurodegenerative diseases, infectious diseases, and gene editing opens doors for breakthrough treatments. Continuous research on delivery methods and combination therapies with other drugs can further enhance siRNA's effectiveness. Increased government funding and public-private partnerships can accelerate research and development, ultimately leading to a wider array of safe and efficacious siRNA-based therapies for various diseases.

SMALL INTERFERING RNA MARKET REPORT COVERAGE:

Global Small Interfering RNA (SiRNA) Market Segmentation: By Type

• Liposome Systemic Therapy

• Nanoparticle-Based Systemic Therapy

The Global Small Interfering RNA (siRNA) Market is Segmented by Type, Liposome Systemic Therapy held the largest market share last year and is poised to maintain its dominance throughout the forecast period. The global market for small interfering RNA (siRNA) is expected to be dominated by the liposome-based systemic therapy segment, which is expected to have a major 53% share throughout the forecast period. Because liposomes can improve the transport of antigens and other stimulatory chemicals to T cells or antigen-presenting cells, they are a useful delivery mechanism for siRNA. Furthermore, liposomes demonstrate the potential to deliver drugs to tumor areas with precision and target particular cell types, enhancing immune responses against tumors. Additionally, they work well as drug-delivery vehicles when used in conjunction with radiation, chemotherapy, and phototherapy. The U.S. Food and Drug Administration (FDA) has approved only one liposomal formulation—nano liposomal irinotecan, or Nivida—for the treatment of metastatic pancreatic cancer as of 2022. Clinically proven liposomes have shown efficacy against pancreatic cancer. This acknowledgment highlights how liposome-based medicines have the potential to completely alter the way that cancer is treated, giving both patients and doctors fresh hope.

Global Small Interfering RNA (SiRNA) Market Segmentation: By End-user

• Hospital

• Research Institutions

• Pharmaceutical and Biotechnology Companies

• Academic Institutions

The Global Small Interfering RNA (siRNA) Market is Segmented by End-use, Research Institutions held the largest market share last year and is poised to maintain its dominance throughout the forecast period. The market for small interfering RNA (siRNA) is expected to have a significant share from research institutions, accounting for 44% of the market over the forecast period. SiRNA has become a potent tool for research organizations studying gene function as well as for therapeutic applications. Because of its adaptability, it may be used both in vivo and in vitro, allowing scientists to explore the complex molecular pathways underlying a wide range of disorders. Moreover, the application of siRNA makes it easier to create novel strategies for reducing off-target effects brought on by unwanted protein binding or accidental mRNA targeting. This accuracy in gene silencing speeds up the deciphering of intricate biological processes while also improving the specificity and effectiveness of experimental interventions. Through the process of deciphering the complex regulation of gene expression, siRNA facilitates a better understanding of basic cellular processes and the etiology of disease. Thus, research institutes are essential to the development of siRNA technology, innovation, and interdisciplinary scientific cooperation. Through ongoing research and development, siRNA has the potential to transform treatment approaches and open new avenues for advancements in precision medicine.

Global Small Interfering RNA (SiRNA) Market Segmentation: By Indication

• Cardiovascular Diseases

• Respiratory Diseases

• Oncology

• Neurodegenerative Diseases

• Infectious Diseases

The Global Small Interfering RNA (siRNA) Market is Segmented by Indication, Oncology held the largest market share last year and is poised to maintain its dominance throughout the forecast period. Shortly, the small interfering RNA (siRNA) industry's oncology segment is expected to take a sizable 39% of the market. Thanks to its promising efficacy shown across several malignancies, including breast and prostate cancer, siRNA is becoming a critical therapeutic method in the fight against various genetic illnesses, especially cancer. Through the utilization of RNA interference, siRNA provides a focused approach to repress the expression of genes implicated in the advancement of cancer, consequently impeding the growth and spread of tumors. SiRNA reduces the risk of off-target effects on healthy tissues while enabling precise control of gene expression within tumor cells. It can be delivered systemically to the entire body or specifically to tissues afflicted by cancer. The therapeutic potential of siRNA is increased by this targeted delivery strategy, allowing for individualized treatment plans based on the needs of each patient and the features of the tumor. Because of their great potential for changing oncological interventions and providing new paths for cancer treatment with minimum toxicity and increased efficacy, siRNA-based therapeutics are very versatile and targeted. SiRNA continues to be at the forefront of cutting-edge strategies in cancer treatment as research and development efforts go forward, advancing the cause of better outcomes and higher quality of life for those suffering from this terrible illness.

Global Small Interfering RNA (SiRNA) Market Segmentation: By Region

• North America

• Asia-Pacific

• Europe

• South America

• Middle East and Africa

The Global Small Interfering RNA (SiRNA) Market is Segmented by Region, North America held the largest market share last year and is poised to maintain its dominance throughout the forecast period. Due to rising healthcare costs in the area, the small interfering RNA (siRNA) market in North America is anticipated to dominate with the greatest share of 37% by 2036. The development of successful and economical siRNA therapeutics has been accelerated by the increased investment in healthcare, supporting market expansion. At the same time, many academic institutions—including prominent ones like Harvard University and the University of California, San Francisco (UCSF)—have started large-scale siRNA research projects. For instance, researchers Shou-wei Ding and Shabihah Shahrudin at the University of California, Riverside have discovered a new isoform of the Dicer enzyme and have shown it to be protective against RNA viruses in stem cell therapies for both humans and mice. This discovery holds great promise for improving siRNA therapies, especially in the fight against illnesses like SARS-CoV-2. Considering this, US healthcare spending increased by more than 2% in 2021 to reach over USD 4 trillion. This significant investment confirms North America's leadership in the global siRNA business and highlights the growing understanding of the critical role novel medicines like siRNA play in improving healthcare outcomes and addressing urgent medical concerns.

COVID-19 Impact Analysis on the Global Small Interfering RNA (SiRNA) Market:

The COVID-19 pandemic has had a conflicting effect on the siRNA business worldwide. Although the first focus switched to the development of COVID-19 vaccines and rapid therapies, it also brought attention to the potential applications of siRNA technology for viral illnesses. The development of siRNA-based treatments for COVID-19 itself paved the way for the wider use of siRNA in the treatment of viral infections. Furthermore, the pandemic prompted improvements in RNA research techniques, which might hasten the creation of siRNA treatments for other illnesses. On the other hand, funding for COVID-19 research may have temporarily halted the development of siRNA for illnesses other than COVID-19. Overall, COVID-19 looks to have a good long-term effect on the siRNA market, and research and development on siRNA may benefit from the pandemic.

Latest Trends/ Developments:

There have been a lot of fascinating advances in the worldwide siRNA industry. The development of next-generation siRNA technology is one important trend. Enhancing siRNA delivery and minimizing off-target effects are the main goals of these developments. For instance, to ensure focused distribution, researchers are creating siRNA conjugated to particular molecules that target sick cells. Furthermore, improvements in the carriers of nanoparticles are improving the stability and cellular uptake of siRNA. The emergence of siRNA-based combination treatments is another trend. It appears possible to create a synergistic impact by combining siRNA with other RNA therapeutics or conventional medications, which could result in more potent treatments for complex conditions. These patterns demonstrate the increasing potential of siRNA technology to transform medicine, as do current clinical trials for a greater variety of ailments.

Key players:

1. Sanofi Genzyme

2. Genecon Biotechnologies Co., Ltd.

3. Arbutus Biopharma Corp

4. Silence Therapeutics AG

5. Sylentis S.A.

6. Olix Pharmaceuticals

7. GlaxoSmithKline

8. Isis Pharmaceuticals/ Ionis Pharmaceuticals

9. BenitecBiopharma Ltd.

10. Bio-Path Holdings Inc.

11. Calando Pharmaceuticals